Sling Therapeutics
Updated: September 19, 2026
CEO - Ryan Zeidan
Country: USA | Funding: $158M (+)
Founded: 2020
Website: https://slingtx.com
Sling Therapeutics develops pharmaceutical treatments for thyroid eye disease, based on Linsitinib licensed by the startup from Astellas. Linsitinib is a tyrosine kinase inhibitor (TKI) designed to block the insulin-like growth factor 1 receptor (IGF-1R). This receptor has been shown to talk to other receptors on the surface of cells behind the eye as well as immune cells, and its overexpression or activation in these cells is what drives the inflammation, swelling and tissue damage characteristic of TED.
Founded: 2020
Website: https://slingtx.com
Sling Therapeutics develops pharmaceutical treatments for thyroid eye disease, based on Linsitinib licensed by the startup from Astellas. Linsitinib is a tyrosine kinase inhibitor (TKI) designed to block the insulin-like growth factor 1 receptor (IGF-1R). This receptor has been shown to talk to other receptors on the surface of cells behind the eye as well as immune cells, and its overexpression or activation in these cells is what drives the inflammation, swelling and tissue damage characteristic of TED.
